Phreesia, Inc. (NYSE:PHR) Shares Bought by Sumitomo Mitsui Trust Holdings Inc.

Sumitomo Mitsui Trust Holdings Inc. raised its stake in Phreesia, Inc. (NYSE:PHR) by 25.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 39,386 shares of the company’s stock after buying an additional 7,976 shares during the quarter. Sumitomo Mitsui Trust Holdings Inc.’s holdings in Phreesia were worth $912,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of PHR. International Assets Investment Management LLC lifted its position in shares of Phreesia by 1,987.3% during the fourth quarter. International Assets Investment Management LLC now owns 1,482 shares of the company’s stock worth $34,000 after purchasing an additional 1,411 shares in the last quarter. Spouting Rock Asset Management LLC lifted its position in shares of Phreesia by 16.5% during the third quarter. Spouting Rock Asset Management LLC now owns 13,381 shares of the company’s stock worth $250,000 after purchasing an additional 1,895 shares in the last quarter. Swiss National Bank lifted its position in shares of Phreesia by 1.7% during the third quarter. Swiss National Bank now owns 112,200 shares of the company’s stock worth $2,096,000 after purchasing an additional 1,900 shares in the last quarter. Raymond James Financial Services Advisors Inc. lifted its position in shares of Phreesia by 18.1% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 15,122 shares of the company’s stock worth $282,000 after purchasing an additional 2,313 shares in the last quarter. Finally, Acadian Asset Management LLC acquired a new stake in shares of Phreesia during the third quarter worth about $53,000. Institutional investors and hedge funds own 92.10% of the company’s stock.

Phreesia Stock Performance

Shares of Phreesia stock opened at $20.47 on Friday. The firm has a market capitalization of $1.15 billion, a P/E ratio of -8.12 and a beta of 0.92. Phreesia, Inc. has a 52 week low of $12.05 and a 52 week high of $34.98. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.02. The firm’s 50 day moving average is $23.80 and its two-hundred day moving average is $21.39.

Phreesia (NYSE:PHR) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.02. The company had revenue of $95.00 million for the quarter, compared to analyst estimates of $93.52 million. Phreesia had a negative net margin of 38.42% and a negative return on equity of 53.33%. The firm’s revenue was up 24.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.72) earnings per share. Research analysts forecast that Phreesia, Inc. will post -1.48 EPS for the current fiscal year.

Insider Transactions at Phreesia

In other news, General Counsel Allison C. Hoffman sold 5,549 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $22.62, for a total transaction of $125,518.38. Following the transaction, the general counsel now directly owns 141,485 shares in the company, valued at $3,200,390.70. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, insider Janet Gunzburg sold 2,817 shares of the firm’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $23.27, for a total transaction of $65,551.59. Following the transaction, the insider now directly owns 40,609 shares in the company, valued at $944,971.43. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, General Counsel Allison C. Hoffman sold 5,549 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $22.62, for a total transaction of $125,518.38. Following the transaction, the general counsel now owns 141,485 shares in the company, valued at $3,200,390.70. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 82,989 shares of company stock worth $1,911,735. Insiders own 5.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on PHR. Stephens reissued an “overweight” rating and set a $28.00 price target on shares of Phreesia in a research report on Friday, March 22nd. Robert W. Baird raised their target price on shares of Phreesia from $30.00 to $31.00 and gave the company an “outperform” rating in a report on Monday, March 18th. JMP Securities raised their target price on shares of Phreesia from $28.00 to $30.00 and gave the company a “market outperform” rating in a report on Thursday, March 21st. DA Davidson reaffirmed a “neutral” rating and issued a $32.00 target price on shares of Phreesia in a report on Friday, March 15th. Finally, Truist Financial initiated coverage on shares of Phreesia in a report on Monday, February 26th. They issued a “buy” rating and a $35.00 target price on the stock. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $31.62.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.